Insight Molecular Diagnostics Inc. 2026 Q1 - Results - Earnings Call Presentation
Insight Molecular Q1 2026 Earnings Call Transcript
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review
Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year
Insight Molecular Published Study In Transplant International Titled "Donor-Derived Cell-Free DNA as a Non-Invasive Readout of Activity Across the Rejection Continuum"
Insight Molecular shares are trading higher after the company announced it completed several milestones to support the GraftAssureDx test kit clinical trial for its planned IVD De Novo submission to the FDA and also received its ISO 13485 certification.
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst
Lake Street Maintains Buy on Insight Molecular, Raises Price Target to $12
iMDx Announces $26.0 Million Registered Direct Offering
Insight Molecular Diagnostics shares are trading lower after the company announced a $26.0 million offering of 4.526 million shares at $5.75 per share.
Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share
Insight ‘congratulated’ STAR working group on organ health testing paper
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.